Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study
- PMID: 12778843
- DOI: 10.1016/s0193-953x(02)00107-7
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study
Abstract
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) attempts to fill in major clinical information gaps and to evaluate the theoretical principles and clinical beliefs that currently guide pharmacotherapy of major depressive disorder. The study is conducted in representative participant groups and settings using clinical management tools that easily can be applied in daily practice. Outcomes include clinical outcomes and health care utilization and cost estimates. Research findings should be immediately applicable to, and easily implemented in, the daily primary and specialty care practices. This article provides the overall rationale for STAR*D and details the rationale for key design, measurement, and analytic features of the study.
Similar articles
-
The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review.Can J Psychiatry. 2010 Mar;55(3):126-35. doi: 10.1177/070674371005500303. Can J Psychiatry. 2010. PMID: 20370962 Review.
-
Enrolling research subjects from clinical practice: ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.Psychiatry Res. 2006 Feb 28;141(2):193-200. doi: 10.1016/j.psychres.2005.04.007. Epub 2006 Feb 2. Psychiatry Res. 2006. PMID: 16457894 Clinical Trial.
-
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.Am J Psychiatry. 2006 Nov;163(11):1905-17. doi: 10.1176/ajp.2006.163.11.1905. Am J Psychiatry. 2006. PMID: 17074942 Clinical Trial.
-
Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.J Med Assoc Thai. 2012 May;95 Suppl 5:S29-37. J Med Assoc Thai. 2012. PMID: 22934442
-
Modelling the cost-effectiveness of pharmacotherapy compared with cognitive-behavioural therapy and combination therapy for the treatment of moderate to severe depression in the UK.Psychol Med. 2015 Oct;45(14):3019-31. doi: 10.1017/S0033291715000951. Epub 2015 Jun 4. Psychol Med. 2015. PMID: 26040631 Review.
Cited by
-
Prediction of treatment outcomes in psychiatry--where do we stand ?Dialogues Clin Neurosci. 2014 Dec;16(4):455-64. doi: 10.31887/DCNS.2014.16.4/fmcmahon. Dialogues Clin Neurosci. 2014. PMID: 25733951 Free PMC article. Review.
-
A brief history of the development of antidepressant drugs: from monoamines to glutamate.Exp Clin Psychopharmacol. 2015 Feb;23(1):1-21. doi: 10.1037/a0038550. Exp Clin Psychopharmacol. 2015. PMID: 25643025 Free PMC article. Review.
-
Improvement in functional outcomes with adjunctive aripiprazole versus placebo in major depressive disorder: a pooled post hoc analysis of 3 short-term studies.Prim Care Companion CNS Disord. 2012;14(6):PCC.12m01394. doi: 10.4088/PCC.12m01394. Epub 2012 Dec 20. Prim Care Companion CNS Disord. 2012. PMID: 23585999 Free PMC article.
-
The STAR*D Trial: It Is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression.Can J Psychiatry. 2015 Jan;60(1):9-13. doi: 10.1177/070674371506000104. Can J Psychiatry. 2015. PMID: 25886544 Free PMC article. No abstract available.
-
Enhancing validity in co-occurring disorders treatment research.Schizophr Bull. 2006 Oct;32(4):655-65. doi: 10.1093/schbul/sbl009. Epub 2006 Jul 18. Schizophr Bull. 2006. PMID: 16849398 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical